MEDCHI, THE MARYLAND STATE MEDICAL SOCIETY
HOUSE OF DELEGATES

Resolution 23-14

INTRODUCED BY: Baltimore County Medical Society

SUBJECT: Transparency of Pharmaceutical Manufacture

Whereas, generic pharmaceuticals fill 84% of prescriptions dispensed in the U.S., but account for just 27% of the total drug spending according to the Generic Pharmaceutical Association; and

Whereas, 80% of active pharmaceutical ingredients are imported into the U.S. and 40% of finished drugs according to the FDA, though there is no good information on the percent of finished generic drugs imported; and

Whereas, even U.S. headquartered generics manufacturers are rushing to expand overseas manufacturing, especially to India; and

Whereas, there have been a number of voluntary recalls and a lack of close monitoring by the FDA or by the monitoring agencies in some foreign countries, especially India and China; therefore be it

Resolved, that MedChi ask our AMA to study quality control and transparency of pharmaceutical manufacturing and advocate for improved monitoring of manufacturing and finished product in countries supplying drugs to the U.S.; and be it further

Resolved, that MedChi ask our AMA to advocate that until such time as U.S. monitoring and foreign manufacturing is deemed adequate, the source country of the active pharmaceutical ingredients and of the manufacture of the finished drugs shall be included on the labels of all medications available to American consumers.

As adopted by the House of Delegates at its meeting on September 27, 2014.